About NetraMark
NetraMark is a company based in Toronto (Canada) founded in 2015 was acquired by Nurosene in October 2021. It operates as a AI-as-a-Service. NetraMark offers products and services including NetraAI. NetraMark operates in a competitive market with competitors including Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.
- Headquarter Toronto, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Netramark Holdings Inc
-
Annual Revenue
$310.66 K (USD)-5.18as on Sep 30, 2025
-
Net Profit
-$3.75 M (USD)-56.72as on Sep 30, 2025
-
EBITDA
-$3.78 M (USD)-51.6as on Sep 30, 2025
-
Latest Funding Round
$2.24 M (USD), Post-IPO
Jan 13, 2026
-
Investors
Nurosene
& 1 more
-
Employee Count
Not available
-
Acquired by
Nurosene
(Oct 12, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NetraMark
NetraMark is a publicly listed company on the CSE with ticker symbol AIAI in Canada, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NetraMark
NetraMark offers a comprehensive portfolio of products and services, including NetraAI.
AI tool used for clinical trial optimization insights.
People of NetraMark
Unlock access to complete
Funding Insights of NetraMark
Investors in NetraMark
NetraMark has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Nurosene and Ontario Brain Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Brain research and care innovation is driven in Ontario.
|
Locked | Locked | Locked | |
|
Psychological health exercises are delivered via a mobile application.
|
Locked | Locked | Locked |
Investor details for NetraMark
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NetraMark
Investment portfolio details for NetraMark
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NetraMark
Detailed financials for NetraMark
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Netramark Comparisons
Peer comparison for NetraMark
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NetraMark
NetraMark operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI-driven drug discovery platform for the treatment of cancer
|
Detailed competitors of NetraMark
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Netramark
Complete news archive for NetraMark
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NetraMark
NetraMark was founded in 2015 and raised its 1st funding round 2 years after it was founded.
NetraMark is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Annual revenue of NetraMark is $310.66K as on Sep 30, 2025.
NetraMark is engaged in providing AI-driven solutions to optimize clinical trial designs. The company operates in the healthcare and technology sectors, offering innovative tools like NetraAI, powered by proprietary Attractor AI algorithms. Insights into patient correlations, treatment efficacy, toxicity, and placebo responses are generated. Trial risks are reduced through enhanced patient stratification and smarter protocol design. The focus is placed on improving decision-making for clinical development teams across various disease areas.
NetraMark's top competitors include Owkin, Formation Bio and XtalPi.
NetraMark offers NetraAI.
Yes, NetraMark is publicly traded on CSE under the ticker symbol AIAI.
NetraMark has 2 investors. Key investors include Nurosene, and Ontario Brain Institute.
The ticker symbol of NetraMark is AIAI on CSE.